Frexalimab

Frexalimab
Monoclonal antibody
TypeWhole antibody
TargetCD40 ligand
Clinical data
AHFS/Drugs.comMonograph
License data
Legal status
Legal status
  • Investigational
Identifiers
PubChem SID
ChemSpider
  • none
KEGG

Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis.